DailyStocks Stock Article Search

https://www.fool.com/investing/2023/12/26/should-you-invest-in-bluebird-bio-right-now/?source=iedfolrf0000001 Dec 26, 2023 - After two December share price crashes, there's no evident cure for Bluebird Bio's ills. 0

https://seekingalpha.com/news/4050298-vyant-bio-files-certificate-of-dissolution-with-state-of-delaware?source=feed_sector_healthcare Dec 26, 2023 - Vyant Bio's Board of Directors has filed for dissolution, ending trading on the OTC. 0

https://seekingalpha.com/news/4057908-annovis-bio-kura-oncology-among-other-healthcare-movers?source=feed_sector_healthcare Jan 24, 2024 - Read about the top gainers and losers in the healthcare sector. 0

https://seekingalpha.com/news/4061462-tourmaline-bio-director-discloses-purchase-of-stake-worth-325m?source=feed_sector_healthcare Feb 01, 2024 - This article discusses insider trading at Tourmaline Bio (TRML), with its director Mark McDade acquiring 100,000 company shares for $3.25 million. 0

https://www.fool.com/investing/2024/03/05/why-bluebird-bio-stock-dived-into-the-red-on-tuesd/?source=iedfolrf0000001 Mar 05, 2024 - The biotech has had a tough time of it over the past few years; a pundit's revised take on the company won't improve that situation. 0

https://www.fool.com/investing/2024/03/13/is-bluebird-bio-stock-a-buy-now/?source=iedfolrf0000001 Mar 13, 2024 - Are you feeling brave? 0

https://www.fool.com/investing/2024/03/18/why-bluebird-bio-stock-flew-higher-than-the-market/?source=iedfolrf0000001 Mar 18, 2024 - The company was thrown a financial lifeline. 0

https://seekingalpha.com/article/4679785-tela-bio-inc-tela-q4-2023-earnings-call-transcript?source=feed_sector_transcripts Mar 21, 2024 - TELA Bio, Inc. (NASDAQ:NASDAQ:TELA) Q4 2023 Earnings Conference Call March 21, 2024 4:30 PM ETCompany ParticipantsLouisa Smith - Vice President, Gilmartin... 0

https://seekingalpha.com/article/4680031-bluebird-bio-is-priced-below-ip-value?source=feed_all_articles Mar 22, 2024 - bluebird bio's stock plummeted by 64% on safety concerns and high pricing for sickle cell treatment. Read why its potential sale value remains higher than its market cap. 0

https://seekingalpha.com/news/4083728-bluebird-bio-stock-falls-accounting-errors?source=feed_sector_healthcare Mar 26, 2024 - bluebird bio (BLUE) faces a significant stock drop after revealing accounting errors that force it to restate financials for 2022 and 2023. Read more here. 0